protein: 0.22 mg/dl (NR:0-0.8), and fecal calprotectin: < 30 (NR:0-30). No red blood cells or polymorphonuclear leukocytes were seen in stool microscopy and the stool culture was negative as well as tests for clostridium difficile and celiac disease. The esophagogastroduodenoscopy was unremarkable except for mild gastritis. Colonoscopy revealed yellowish-white, flat elevated lesions with patchy involvement of the ascending colon (Fig. 1) . The histopathological examination of the biopsy of the lesions was consistent with colonic malakoplakia (Fig. 2) . In the random biopsies taken of normal-appearing mucosa of the ascending colon, descending colon and rectum, the absence of microscopic colitis or amyloidosis was documented in the histopathological examination. The immunosuppressive medications were modified (Mycophenolate mofetil was stopped, tacrolimus dose was decreased to 1 mg/day, and azathioprine 75 mg/day was initiated), but the diarrhea continued during the subsequent three weeks. Budesonide 9 mg/day was started for diarrhea and the tacrolimus dose was increased to 2 mg/day as ordered by the consultant nephrologist. At the end of the third week of budesonide treatment, the patient had improved dramatically and was symptom-free. Budesonide treatment was continued for three more months and then stopped gradually. The diarrhea symptoms did not recur during the ninemonth follow-up after treatment cessation.
Malakoplakia is a chronic inflammatory disorder that can affect various parts of the body, including the urinary tract, gastrointestinal tract, lymph nodes, lung, brain, pancreas, bone, and skin. The gastrointestinal system is the second most common site of involvement of the disease after the urinary tract, and the colon and rectum are predominantly affected. Although the pathogenesis is not completely known, gram-negative bacterial infections, especially Escherichia coli, and altered inflammatory activation have been considered responsible in the disease etiology. Malakoplakia is usually encountered with comorbid conditions such as malignancies, organ transplantation, sarcoidosis, tuberculosis, liver diseases, ulcerative colitis, malnutrition, mycotic infections, and immunodeficiency syndromes [1, 2] . The case is here reported of colonic malakoplakia in a kidney transplant recipient. There are very few reports in literature of colonic malakoplakia in patients with renal transplantation [3, 4] . The major contributing factor for the development of malakoplakia could be intense immunosuppressive agent use in this population. The patients can be asymptomatic or present with fever, diarrhea, vomiting, abdominal pain, constipation, gastrointestinal bleeding, and intestinal obstruction. The diagnosis of colonic malakoplakia can be made from the observation of endoscopic lesions and histopathological examination. Colonoscopic findings may vary from yellowish-white mucosal plaques, as in the current case, to nodular, polypoid, ulcerated, or mass-like lesions. The presence of von Hansemann cells (clusters of histiocytes with abundant eosinophilic cytoplasm) and Michaelis-Gutmann bodies (intracytoplasmic basophilic calcified inclusions) are characteristic findings on histopathological examination [1] [2] [3] . Treatment options include the reduction of the immunosuppressive regime, and the use of cholinergic agonists such as bethanechol, and ascorbic acid to improve macrophage function. Long-term use of antibiotics (trimethoprim/sulphamethoxazol, ciprofloxacin, and rifampicin) have also been used with some success, as well as endoscopic or surgical excision of the lesion [1] [2] [3] [4] [5] . In the current patient, the diarrhea did not improve with the modification of immunosuppressive agents. Antibiotherapy was not initiated as antibiotics had been used for diarrhea (Metronidazole, ciprofloxacin, and rifaximin) several times before admission. However, the budesonide was used for three months and the diarrhea was completely resolved. To the best of our knowledge, this is the first report of the successful use of budesonide in the treatment of colonic malakoplakia. Budesonide is a synthetic glucocorticoid with local anti-inflammatory effects. The oral form of budesonide has a high first-pass effect with minimum systemic absorption that does not lead to systemic immunosuppression (Systemic immunosuppression in the current case due to its local antiinflammatory activity which may correct malakoplakia, which is related to altered is contributory factor for colonic malakoplakia). It converts the active drug form in the distal small intestine and proximal colon and the anti-inflammatory effects of budesonide are especially seen in these localizations [6] . Budesonide was used inflammatory activation of the colon, without causing systemic immunsupression. In addition, the malakoplakia-related lesions in this case were on the ascending colon, where budesonide is known to have a higher anti-inflammatory effect.
In conclusion, colonic malakoplakia should be considered in the differential diagnosis of chronic diarrhea in immunocompromised patients such as renal transplant recipients and budesonide seems to be an effective treatment choice for this indication. However, further research is needed to clarify the effects of budesonide in the treatment of colonic malakoplakia.
Informed consent was obtained from the patient.
